aripiprazole/sertraline

{{Short description|Medication under development by Otsuka Pharmaceutical}}

{{Drugbox

| image =

| width =

| caption =

| type = combo

| drug_name =

| component1 = Aripiprazole

| class1 = Atypical antipsychotic

| component2 = Sertraline

| class2 = Selective serotonin reuptake inhibitor

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US = IND

| routes_of_administration = By mouth

| CAS_number =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = ASC-01

}}

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).{{cite web | title = Aripiprazole/sertraline - Otsuka Pharmaceutical | url = http://adisinsight.springer.com/drugs/800039778 | work = AdisInsight | publisher = Springer Nature Switzerland AG }} It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.{{cite journal | vauthors = Kamdijima K, Kimura M, Kuwahara K, Kitayama Y, Tadori Y | title = Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder | journal = Psychiatry and Clinical Neurosciences | volume = 72 | issue = 8 | pages = 591–601 | date = August 2018 | pmid = 29660207 | doi = 10.1111/pcn.12663 | s2cid = 4958169 | doi-access = free }} In July 2017, it was in preregistration in Japan for the treatment of MDD. However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.{{cite web |title=Aripiprazole/sertraline - Otsuka Pharmaceutical - AdisInsight |url=https://adisinsight.springer.com/drugs/800039778 |website=adisinsight.springer.com}}